Sugarcane bagasse dietary fiber as an adjuvant therapy for stable chronic obstructive pulmonary disease: a four-center, randomized, double-blind, placebo-controlled study  by Miao, Liu et al.
TOPIC
JTCM |www. journaltcm. com August 15, 2016 |Volume 36 | Issue 4 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2016 August 15; 36(4): 418-426
info@journaltcm.com ISSN 0255-2922
© 2016 JTCM. All rights reserved.
CLINICAL STUDY
Sugarcane bagasse dietary fiber as an adjuvant therapy for stable
chronic obstructive pulmonary disease: a four-center, randomized,
double-blind, placebo-controlled study
Liu Miao, Zheng Fengjie, Ni Lei, Sun Yan,Wu Ruohan, Zhang Tianyu, Zhang Jinchao, Zhong Xianggen, Li Yuhang
aa
Liu Miao, Zheng Fengjie, Ni Lei, Sun Yan, Wu Ruohan,
Zhang Tianyu, Zhang Jinchao, Zhong Xianggen, Li Yu-
hang, School of Preclinical Medicine, Beijing University of
Chinese Medicine, Beijing 100029, China
Supported by the National Basic Research Program of Chi-
na: Study on Mechanism of Lung-Intestine Communication
in View of the Theory of COPD Treatment Based on Intestine
(No. 2009CB522704)
Correspondence to: Prof. Li Yuhang, School of Preclinical
Medicine, Beijing University of Chinese Medicine, Beijing
100029, China. liyuhang@bucm.edu.cn
Telephone: +86-10-64287503; +86-15210694921
Accepted: September 21, 2015
Abstract
OBJECTIVE: To evaluate the efficacy and safety of
sugarcane bagasse dietary fiber as an adjuvant
therapy for improving quality of life in patients
with stable chronic obstructive pulmonary disease
(COPD).
METHODS: This was a multicenter, randomized,
double-blind, placebo-controlled trial. A total of
196 participants were randomized into a trial group
(treated with 6 g/day sugarcane bagasse plus con-
ventional treatment, n = 98) and a control group
(treated with placebo plus conventional treatment,
n = 98). All efficacy analyses were performed ac-
cording to the intention-to-treat (ITT) principle. A
per-protocol analysis set (PPS) was used to analyze
the cases that completed the clinical trial with
good compliance. The trial period was 30 days,
with a 6-month follow-up. Pre- and post-treatment
pulmonary symptom scores (cough, sputum,
wheezing, and dyspnea) were recorded for both
groups. The St. George's Respiratory Questionnaire
(SGRQ) and the modified Medical Research Coun-
cil (mMRC) dyspnea scale were assessed before
treatment and at the end of the 6-month fol-
low-up.
RESULTS: The ITT population was 178 and the PPS
population was 166. Post-treatment pulmonary
clinical symptoms and severity of dyspnea (mMRC
and SGRQ evaluation) were significantly improved
in both the trial group and the control group (ITT
and PPS: P < 0.05). However, there was no statisti-
cal difference between the two groups in
post-treatment pulmonary symptoms and mMRC.
There was a greater reduction in the SGRQ sub-
scales of activity, effect and total score in the trial
group compared with the control group (ITT and
PPS: P < 0.01). There was no statistical difference
in pre- and post-treatment safety variables in ei-
ther group.
CONCLUSION: Sugarcane bagasse combined with
conventional treatment improved quality of life in
patients with stable COPD. Sugarcane bagasse ap-
pears to be a safe herbal medicine with potential
for treating patients with stable COPD when taken
orally as an adjuvant therapy.
Key words: Saccharum; Pulmonary disease, chron-
ic obstructive; Randomized clinical trial; Medicine,
Chinese Traditional
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
characterized by constant disruption of airflow into
and out of the lungs. COPD induces morbidity and
mortality and places a tremendous burden on patients,
health-care systems and society.1 COPD not only dis-
rupts psychological, emotional and social function, but
also imposes restrictions on daily activities, and serious-
ly influences patients' health-related quality of life
(HRQoL).2 Based on current trends, COPD is predict-
ed to become the fifth top burden in the world by
2020.3 Zhong et al 4 reported that the prevalence of
COPD in China in people 40 years or older was 8.2%,
or 43 million based on China's population in
2002-2004.
COPD management is aimed at relieving symptoms,
preventing disease progression, treating complications
and exacerbations, improving exercise tolerance and
health status, and reducing mortality.5 Therapeutic mo-
dalities encompass pharmacologic and non-pharmaco-
logic therapies including oxygen therapy, ventilator sup-
port, surgery, and lifestyle changes. Pharmacologic ther-
apy can relieve COPD symptoms, reduce the frequen-
cy and severity of exacerbations, and improve exercise
tolerance and health status; however, these medications
can also cause side effects. For example, anticholiner-
gics can lead to dry mouth, methylxanthines are associ-
ated with cardiac arrhythmias,6 and long-term use of in-
haled corticosteroids is related to higher prevalence of
hoarseness, oral candidiasis, and skin bruising.7 Thus,
new COPD therapies are needed.
In China, Traditional Chinese Medicine (TCM) is
commonly used to treat COPD. The TCM treatment
approach is founded on the concept put forth in the
ancient classic Huang Di Nei Jing that each internal or-
gan has an interrelated organ.8 Based on this concept,
the large intestine is the paired organ of the lung.
Thus, one TCM approach widely used in treating lung
diseases such as COPD is to promote bowel regularity.
Chinese sugarcane (Saccharum sinense Roxb.) has been
used in China as both food and medicine for more
than 2000 years. Ben Cao Gang Mu, one of the most
complete tomes on TCM theory and treatment, re-
ports that sugarcane relaxes the large intestine.9 In-
spired by this, our previous research found that a di-
etary fiber preparation made from sugarcane bagasse
prevented and treated the rat model of COPD.10
To verify this new treatment in humans, we undertook
a multicenter, randomized, double-blind, placebo-con-
trolled clinical study to evaluate the efficacy and safety
of sugarcane bagasse dietary fiber as an adjuvant thera-
py in patients with stable COPD.
METERIALS ANDMETHODS
Ethics and trial registration
This trial was conducted according to the guidelines of
the Declaration of Helsinki.11 This trial was registered
with the Chinese Clinical Trial Registry (ChiC-
TR-TRC-09003117), and was approved by the Ethical
Research Committee of the Dongzhimen Hospital Af-
filiated to Beijing University of Chinese Medicine
(DZMSP20090302). All participants signed informed
consent forms, which are on file at the Department of
Preclinical Medicine, Beijing University of Chinese
Medicine, Beijing, China.
Participants
In this study, 196 out- and in-patients with stable
COPD were recruited from November 2009 to Febru-
ary 2013 from four hospitals in China: 58 cases from
the Dongzhimen Hospital affiliated to Beijing Universi-
ty of Chinese Medicine (Beijing, 29.6% ), 78 cases
from Hebei Provincial Hospital of Traditional Chinese
Medicine (Shijiazhuang, 39.8%), 40 cases from the Af-
filiated Hospital of Gansu University of Traditional
Chinese Medicine (Lanzhou, 20.4% ), and 20 cases
from the Affiliated Hospital of Liaoning University of
Traditional Chinese Medicine (Shenyang, 10.2%).
Patients were considered eligible if they met all of the
following inclusion criteria: (a) diagnosis of COPD
(post-bronchodilator FEV1/FVC less than 70%) based
on the Global Initiative for Chronic Obstructive Lung
Disease (GOLD; 2007)12 and Chinese Society of Re-
spiratory Diseases;13 (b) stable COPD; (c) < 80 years
old at the time of study commencement; and (d) par-
ticipating of their own free will after signing an in-
formed consent form. Patients meeting any of the fol-
lowing criteria were excluded from the study: (a) chron-
ic enteritis or diarrhea (> three times/day) with concur-
rent dizziness and fatigue; (b) intractable constipation
and use of stimulant laxatives such as Dahuang (Radix
Et Rhizoma Rhei Palmati), Fanxieye (Folium Sennae),
castor oil, or phenolphthalein; (c) severe comorbid dis-
ease such as peritonitis, mechanical intestinal obstruc-
tion, intestinal stenosis, severe hemorrhoids, hernia,
post-colorectal surgery, anal mucosal inflammatory ede-
ma, severe anemia, aneurysms, intestinal bleeding or
perforation, colorectal cancer, liver cirrhosis, anal fistu-
la, acute cerebral hemorrhage, acute left heart failure,
gastrointestinal hemorrhage, acute renal failure, or
aplastic anemia; (d) airflow limitation because of bron-
chiectasis, cystic pulmonary fibrosis, lung cancer, active
tuberculosis or other disorders; (e) serious heart, hepat-
ic, renal or hematopoietic diseases; (f ) having recently
taken immunosuppressant medication; (g) pregnant or
breast-feeding; (h) psychiatric or any type of neurologi-
cal deficit (cognitive impairment or aphasia) that ren-
dered patients unable to understand the nature, scope
and possible consequences of the study; (i) digestive ob-
stacles, malnutrition, physical weakness or dehydra-
tion; and (j) allergy to the experimental drug.
Participants could withdraw from the study at any
time for any reason. Researchers recorded the reasons
for withdrawal or early discontinuation, although every
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effort was made to ensure adherence during the trial. If
adverse events (AEs) occurred, researchers discussed
whether the symptoms were severe enough to warrant
termination of the participant from the trial. In gener-
al, termination criteria were: (a) non-adherence to the
treatment or follow-up protocols; (b) using other medi-
cations during the trial that might impact the results or
cause adverse effects; (c) adverse effects that precluded
continuation in the trial; and (d) not meeting the entry
criteria.
Sample size
As this was an exploratory study, there were no existing
clinical data on the use of sugarcane bagasse for the
treatment of stable COPD available as a reference for
our trial. Therefore, we referred to literature on analog
medicines used for stable COPD and hypothesized the
effect rate for calculating sample size.14,15 The effect rate
was hypothesized to be 70% for conventional medicine
plus placebo and 90% for conventional medicine plus
sugarcane bagasse. A 1∶1 parallel design was used for
the control group and the trial group. With a one-sid-
ed significance level of 5%, a statistical power of 90%,
and an assumed drop-out rate of approximately 20%,
we needed to randomly assign 98 participants to each
group.
Medicine preparation
Fresh sugarcane was purchased from the Sugarcane
Quality Supervision, Inspection and Test Center, Min-
istry of Agriculture of the People's Republic of China,
Beijing, China. Sugarcane bagasse was made from fresh
sugarcane into pills (a standard 1-g pill contained 0.5 g
sugarcane bagasse/pill, plus the same other ingredients
as in the placebo pill) as described by Beijing Zheng
Yuan Ju Xin Health Food Technology Development
Co., Ltd., Beijing, China (batch numbers: 20090501,
20090502, 20090503).16 This supplier was also com-
missioned to prepare the placebo tablet, which was
made of skim milk powder with a sugar and dextrin
coating, and was designed to have a similar taste, smell,
and appearance to the sugarcane bagasse pills.
Randomization and blinding
Randomization was generated by SAS 8.0 software
(SAS Institute Inc., Cary, NC, USA). To ensure alloca-
tion concealment, the drugs were packaged by an inde-
pendent clinical statistician. Participants were random-
ized into one of the two groups when they met the in-
clusion criteria and signed the informed consent form.
Participants and investigators were blinded until the
end of the trial. In addition, opaque and sealed emer-
gency letters were printed in accord with the random-
ized list. In the event of a clinical emergency, the partic-
ipant's randomization code and group allocation could
be identified using the emergency envelope. A single in-
vestigator was assigned at each center to record and se-
cure randomization information; this individual did
not have contact with other trial investigators, thus en-
suring that there was no investigator effect on enroll-
ment and randomization. An independent clinical stat-
istician completed the outcome assessments; this indi-
vidual was blinded to randomization and did not par-
ticipate in any other part of the trial.
Interventions
All participants in both groups were given convention-
al medication based on GOLD12 and Chinese Society
of Respiratory Diseases13 recommendations (Table 1).
The trial group was given conventional medication plus
sugarcane bagasse pills orally (six pills twice daily for
30 days). The control group was given conventional
medication plus placebo (six pills twice daily for 30 days).
Participants did not receive any intervention during
the 6-month follow-up period. A telephone hotline
was established to address participant queries or issues.
Outcome measures
Based on previous nationwide research (Symptom Stan-
dardization of Traditional Chinese Medicine, No.
2003CB517100, supported by the National Basic Re-
search Program of China), a case report form was devel-
oped based on literature research,17 a pilot survey, and
expert opinions. The details were as follows:
Symptom scores: this was the primary measure in the
study. Based on the Likert response scale18 as well as
symptom quantification and classification from the
Guide to New Traditional Chinese Medicine Research,19
values of 0, 2, 4, and 6 respectively were assigned to
COPD stage
Ⅰ: mild
Ⅱ: moderate
Ⅲ: severe
Ⅳ: very severe
Lung function
FEV1/FVC < 70%; FEV1 ≥ 80% of predicted
value
FEV1/FVC < 70%; FEV150% - < 80% of
predicted value
FEV1/FVC < 70%; FEV1 30% - < 50% of
predicted value
FEV1/FVC < 70%; FEV1 < 30% of predicted
value, or FEV1 < 50% of predicted value plus
chronic respiratory failure
Therapya
Initiate risk factor reduction; use short-acting bronchodilator as
needed, i.e., salbutamol, albuterol
Add one or more long-acting bronchodilators as needed, i.e.,
formoterol; add rehabilitation
Add inhaled glucocorticoids for repeated exacerbations, i.e.
salmeterol or formoterol dry powder
Add long-term oxygen for chronic respiratory failure; consider
surgery
Notes: abased on recommendations by the Global Initiative for Chronic Obstructive Lung Disease.12 COPD: chronic obstructive pulmo-
nary disease; FEV1/FVC: the ratio of forced expiratory volume in 1 second to forced vital capacity; FEV1%: FEV1 percentage of the predict-
ed value.
Table 1 Therapy given according to stage of chronic obstructive pulmonary disease
420
Liu M et al. / Clinical Study
JTCM |www. journaltcm. com August 15, 2016 |Volume 36 | Issue 4 |
the four symptom grades of none, mild, moderate, and
severe. Major pulmonary symptoms (cough, sputum,
wheezing, and dyspnea) were then evaluated and re-
ported by patients. Pre- and post-treatment symptom
scores were recorded.
Health-related quality of life: HRQoL was evaluated us-
ing the Chinese translation of the St. George's Respira-
tory Questionnaire (SGRQ).20 The SGRQ is composed
of symptoms, activity, impact of disease, and total
score, and was designed to quantify and measure the
impact of chronic respiratory disease on patients' quali-
ty of life. Health status as measured by the SGRQ was
therefore used as a co-primary endpoint in the trial.
SGRQ scores were recorded pre-treatment and at the
6-month follow-up visit.
Modified Medical Research Council (mMRC) dyspnea
scale: the mMRC dyspnea questionnaire is related to
other measures of health status21 and predicts future
mortality risk.22 Assessment of the degree of breathing
difficulty is crucial to understanding the severity of the
disease, patients' health status, and to evaluate the ef-
fects of intervention. For all participants, dyspnea sever-
ity was assessed according to the mMRC scale pre-treat-
ment and at the sixth follow-up visit.23
Safety assessments: pre- and post-treatment safety as-
sessments were performed. Routine blood, urine, and
stool samples were collected. Liver and kidney function
tests as well as electrocardiography (ECG) were carried
out. All AEs that occurred during the study, including
the treatment and follow-up periods, were assessed and
recorded.
Data entry and statistical analysis
Data were entered by two independent researchers us-
ing EpiData 3.0 software (The EpiData Association,
Odense, Denmark). All efficacy analyses were per-
formed on the intention-to-treat (ITT) population,
which included all patients who were randomized and
received treatment. Partially missing data of the clinical
evaluation were resolved with the principle of the last
observation carried forward. A per-protocol analysis set
(PPS) was adopted to analyze the cases that completed
the clinical trial with good compliance. All statistical
tests were two-tailed, and P < 0.05 was taken to be sta-
tistically significant. Enumeration data were represent-
ed as a percentage and evaluated by the chi-square test.
Between-group difference after treatment was assessed
by analysis of variance and/or analysis of covariance
represented by the mean ± standard deviation ( xˉ ± s).
Within-group difference between pre- and post-treat-
ment values was assessed using the paired t-test. Statisti-
cal analyses were performed using SPSS version 17.0
software (SPSS, Inc., Chicago, IL, USA).
RESULTS
Study population
A total of 219 patients were screened for entry into the
study, with 23 deemed ineligible. Of the remaining
196 patients, one dropped out because of heartburn
and six were lost to follow-up. Therefore, 189 patients
completed the entire 30-day treatment and 6-month
follow-up. Five participants did not adhere to proto-
cols, with less than 240 (2/3) of 360 pills taken (com-
pliance < 80%), and 18 were excluded from the effica-
cy analysis because they failed to meet the inclusion cri-
teria. Therefore, the final number in the PPS was 166,
with 84 patients in the trial group and 82 patients in
the control group. The final ITT population was 178,
with 91 in the trial group and 87 in the control group
(Figure 1).
There was no significant pre-treatment difference be-
tween the trial group and the control group in age, sex,
body mass index, educational status, smoking status,
GOLD classification of lung function, course of dis-
ease, symptom exacerbations, or whether the partici-
pants had received the influenza vaccine (Table 2).
Symptoms
Within the trial and the control group, the mean
post-treatment pulmonary symptom values were signif-
icantly decreased compared with pre-treatment values
(P < 0.001). However, there was no significant differ-
ence between the two groups (ITT: －0.42, 95% CI:
－1.66 to 0.82, P = 0.506; PPS:－0.45, 95% CI:－1.74
to 0.84, P = 0.490) (Table 3).
Health-related quality of life
The four subscale scores of the SGRQ (symptoms, ac-
tivity, impact of disease, and total score) were signifi-
cantly reduced in both the trial and the control group
compared with pre-treatment values (ITT and PPS:
P < 0.05). After the 30-day treatment period, three
SGRQ subscale scores (activity, impact of disease, and
total score) were significantly lower in the trial group
compared with the control group (activity: ITT: P <
0.001 and PPS: P = 0.001; impact of disease: ITT: P =
0.002 and PPS: P = 0.002; total score: ITT: P = 0.001
and PPS: P < 0.001). The subscale score of symptoms
was more obviously reduced in the trial group than in
the control group, but this difference was not statistical-
ly significant (ITT: －6.20, 95% CI: －12.54 to 0.14,
P = 0.055; PPS:－5.94, 95% CI:－12.19 to 0.31, P =
0.062; Table 4).
Dyspnea grade
Compared with pre-treatment, dyspnea improved sig-
nificantly in both the trial group (ITT: P = 0.006, PPS:
P = 0.005) and the control group (ITT: P = 0.019;
PPS: P = 0.021); however, there was no significant dif-
ference between the two groups after treatment (ITT:
P = 0.779, PPS: P = 0.627, Table 5).
Safety
Treatment was discontinued because of an AE (heart-
burn) in one of 91 (1%) patients in the trial group ver-
sus no patients in the control group (P = 0.327). There
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was no statistical difference in routine blood, urine,
and stool testing, liver and kidney function, or ECG in
both groups before and after treatment (Table 6).
DISCUSSION
To our knowledge, this is the first trial to investigate
sugarcane bagasse dietary fiber as an adjuvant therapy
for stable COPD. The overall clinical interventions
were effective; pulmonary clinical symptom scores and
severity of dyspnea grade on mMRC and SGRQ evalu-
ation were significantly improved after treatment in
both the sugarcane bagasse trial group and the placebo
control group. Compared with those of the control
group, the symptom scores and mMRC of the trial
group appeared slightly improved; however, there was
no statistical difference between the two groups after
treatment. The post-treatment SGRQ subscales of ac-
tivity, impact of disease and total score were significant-
ly more reduced in the trial group than in the control
group, demonstrating that sugarcane bagasse dietary fi-
ber was an effective adjuvant therapy to conventional
COPD medication in improving HRQoL.
Quality of life has emerged as a significant consider-
ation in disease treatment and prevention in recent de-
cades.24,25 COPD has a considerable influence on pa-
tients' physical and emotional well-being, social activi-
ty, and work. Health status is closely related to mortali-
ty and is independent of airflow limitation or age.26 Im-
proving quality of life is a desirable indicator in manag-
ing patients with COPD. The SGRQ measures the ef-
fect of chronic respiratory disease on patients'
HRQoL.27 We found no significant difference between
the trial and the control group in post-treatment
SGRQ pulmonary symptom scores; however, the
SGRQ subscales of activity, impact of disease and total
score, which were concerned with physical activities
that either cause or are limited by breathlessness and ex-
pectations for health and disturbance of daily life, were
significantly more reduced in the trial group compared
with the control group. Adjunctive therapy with sugar-
cane bagasse had a better effect than conventional med-
icine alone in mitigating quality of life.
Several lines of evidence have independently suggested
that higher fiber intake is related to better lung func-
tion and lower risk of developing COPD.28,29 However,
Figure 1 Flowchart of study
ITT: intention-to-treat; PPS: per protocol set.
Assessed for eligibility
(n = 219)
Excluded (n = 23)
Did not meet inclusion criteria (n = 13)
Elected not to participate: (n = 8)
Other reasons: (n = 2)
Randomized
(n = 196)
Trial group
(n = 98)
Control group
(n = 98)
7 Withdrew
Non-adherent (n = 2)
AEs (n = 1)
Without explanation (n = 4)
5 Withdrew
Non-adherent (n = 3)
Without explanation (n = 2)
91 (93%)
Completed the study
93 (95%)
Completed the study
Did not meet inclusion
criteria (n = 7)
Did not meet inclusion
criteria(n = 11)
Data analysis
ITT (n = 91)
PPS (n = 84)
Data analysis
ITT (n = 87)
PPS (n = 82)
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the exact mechanism between COPD and dietary fiber
is still unclear. Our study was designed to evaluate the
hypothesis that sugarcane bagasse, which is used as di-
etary fiber and a laxative, could improve COPD symp-
toms. Our hypothesis was based on a fundamental
TCM theory in which the lung and large intestine in-
teract with one another physiologically and pathologi-
cally. This phenomenon appears to also occur in West-
ern (conventional) Medicine.30,31 Sugarcane bagasse is
the fibrous byproduct that remains after sugar cane
stalks are crushed to extract juice. The fibrous portion
of bagasse is composed mainly of cellulose, hemicellu-
lose, and lignin. Such types of soluble fiber are not as-
similated by the intestine, and when ingested they in-
crease stool bulk and keep the stool moist, improving
stool transit time to prevent and treat constipation.32-34
Our trial indicates that the beneficial effect of sugar-
cane bagasse dietary fiber in improving quality of life
in patients with stable COPD could be achieved
through regulation of the intestinal environment.
The anti-inflammatory and antioxidant properties of fi-
ber are another potential mechanism for the efficacy of
sugarcane bagasse in improving quality of life in pa-
tients with stable COPD.35 Airway inflammation is the
primary pathogenic factor for both parenchymal de-
struction and airway remodeling in COPD.36 Previous
research has demonstrated that increased intake of total
dietary fiber decreased the concentration of interleu-
kin-6, interleukin-18 and C-reactive protein.37-40 King
indicated that dietary fiber reduced lipid oxidation,
which in turn is associated with decreased inflamma-
tion.41 Our previous research found that sugarcane ba-
Table 2 Baseline characteristics of participants ( xˉ ± s)
Item
Age (years)
Male/Female (n)
BMI (kg/m2)
Body temperature (℃),
Frequency of exacerbation
Tobacco history
Disease severity
Course of disease
Variable
Currently smoking [n (%)]
Never smoked [n (%)]
Ever smoked [n (%)]
No. of packs/year
FEV1/FVC
GOLD stageⅠ [n (%)]
GOLD stageⅡ [n (%)]
GOLD stageⅢ [n (%)]
GOLD stageⅣ [n (%)]
> 5 years
≤ 5 years
Influenza vaccinations (n)
Trial group (n = 91)
62.89±9.53
64/27
23.60±2.71
36.47±0.44
2.18±0.68
12 (13.1)
40 (44.0)
39 (42.9)
186.91±230.72
59.18±10.14
5 (5.5)
60 (65.9)
21 (23.1)
5 (5.5)
78 (85.7)
13 (14.3)
47/44
Control group (n = 87)
63.77±9.58
58/29
23.21±2.71
36.38±0.24
2.24±0.59
10 (11.5)
33 (37.9)
44 (50.6)
155.65±189.84
58.02±11.61
7 (8.0)
53 (60.9)
20 (23.1)
7 (8.0)
80 (92.0)
7 (8.0)
49/38
Notes: trial group was treated with conventional medication plus sugarcane bagasse pills orally (six pills twice daily for 30 days); control
group was treated with conventional medication plus placebo (six pills twice daily for 30 days). BMI: body mass index; FEV1/FVC: the ra-
tio of forced expiratory volume in 1 second to forced vital capacity; GOLD: global initiative for chronic obstructive lung disease.
Pulmonary
symptoms a
ITT
PPS
Trial group
Pre
10.40 (4.52)
10.48 (4.58)
Post
5.30 (3.96)
5.29 (3.98)
Mean Db
－5.10 (5.64)
－5.19 (5.82)
Control group
Pre
10.74 (4.10)
10.76 (4.21)
Post
5.86 (4.38)
5.78 (4.48)
Mean Dc
－4.87 (5.27)
－4.98 (5.39)
Treatment effectb
(95% CI; P value)
－0.42
(－1.66, 0.82; 0.506)
－0.45
(－1.74, 0.84; 0.490)
Notes: trial group was treated with conventional medication plus sugarcane bagasse pills orally (six pills twice daily for 30 days); control
group was treated with conventional medication plus placebo (six pills twice daily for 30 days). Mean D: mean difference; CI: confidence
interval; ITT: intention-to-treat; PPS: per protocol set. Data are presented as mean (SD). aThe ITT population was 91 in the trial group
and 87 in the control group; the PPS population was 84 in the trial group and 82 in the control group. bCovariance analysis estimate with
95% CI for the difference. cP < 0.001 for change between pre- and post-treatment value (within-group difference analyzed by the paired
t-test).
Table 3 Comparison of pre- and post-treatment symptom scores between the trial and the control group ( xˉ ± s)
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gasse had beneficial effects for COPD rats in reducing
malondialdehyde, increasing superoxide dismutase ac-
tivity, and improving airflow limitation.10 Taken togeth-
er, these findings suggest that anti-inflammatory and
antioxidant properties might be the potential mecha-
nism for the effect of sugarcane bagasse on improving
HRQoL in patients with COPD.
Our study found that sugarcane bagasse pills were a
Table 5 Comparison of the dyspnea grades in the trial and the control group [n (%)]
Modified Medical
Research Council
(mMRC) scalea
Pre-treatment
0
1
2
3
4
Post-treatment
0
1
2
3
4
P valuec
Intend to treat
Trial group
(n = 91)
19 (20.88)
34 (37.36)
20 (21.98)
16 (17.58)
2 (2.20)
29 (31.87)
45 (49.45)
13 (14.29)
3 (3.30)
1 (1.10)
0.006
Control group
(n = 87)
19 (21.84)
34 (39.08)
18 (20.69)
16 (6.90)
0 (0)
30 (34.48)
40 (45.98)
12 (13.79)
5 (5.75)
0 (0)
0.019
P valueb
0.733
0.779
Per protocol set
18 (21.69)
31 (37.35)
17 (20.48)
16 (19.28)
2 (2.41)
28 (33.73)
42 (50.60)
10 (12.05)
3 (3.61)
1 (1.20)
0.005
Trial group
(n = 84)
Control group
(n = 82)
18 (21.95)
33 (40.24)
15 (18.29)
16 (19.51)
0 (0)
29 (35.37)
38 (46.34)
10 (12.20)
5 (6.10)
0 (0)
0.021
P valueb
0.640
0.627
Notes: trial group was treated with conventional medication plus sugarcane bagasse pills orally (six pills twice daily for 30 days); control
group was treated with conventional medication plus placebo (six pills twice daily for 30 days). Rank-sum test for two independent sam-
ples was used for comparison of dyspnea grade pre- and post-treatment. Values are presented as n (%). aModified Medical Research Coun-
cil scale:19 0: not troubled by breathlessness except with strenuous exercise; 1: short of breath when walking quickly on level ground or
walking up a slight hill; 2: walks slower than others of the same age because of breathlessness or has to stop to catch breath when walking
on level ground; 3: stops to catch breath after walking about 100 meters/yards or after a few minutes on level ground; 4: too breathless to
leave the house or breathless when dressing or undressing. bP values for the comparison of the pre- and post-treatment values in the trial
group with those of the control group. cP values for the comparison of the pre-treatment values with the post-treatment values in the trial
and control groups.
Table 4 Comparison of St. George's Respiratory Questionnaire scores in the trial and the control group ( xˉ ± s)
SGRQ1
Symptom
Activity
Impact
Total
ITT
PPS
ITT
PPS
ITT
PPS
ITT
PPS
Trial group
Pre
57.00
(22.56)
56.11
(22.87)
47.21
(20.64)
47.18
(20.79)
36.24
(22.18)
36.26
(22.47)
44.13
(19.48)
42.80
(19.96)
Post
41.11
(21.94)
39.18
(21.20)
30.98
(17.17)
31.17
(16.78)
19.49
(16.28)
18.23
(15.17)
26.39
(16.41)
24.43
(14.47)
Mean D
－15.89
(30.51)a
－16.93
(31.93)a
－16.23
(22.99)a
－17.01
(25.62)a
－16.75
(25.95)a
－18.23
(26.46)a
－17.10
(23.68)a
－18.37
(24.15)a
Control group
Pre
54.42
(21.56)
53.31
(21.60)
48.25
(21.53)
47.89
(21.97)
37.60
(20.72)
36.83
(20.80)
45.23
(18.92)
42.84
(18.87)
Post
47.41
(20.76)
45.50
(19.79)
46.07
(21.97)
40.79
(21.84)
28.46
(20.32)
26.60
(19.29)
36.52
(20.10)
33.88
(18.75)
Mean D
－7.01
(31.94)b
－7.81
(32.68)b
－6.18
(28.73)b
－7.10
(29.21)b
－9.14
(25.58)a
－10.23
(25.68)a
－7.95
(25.59)a
－8.96
(25.86)a
Treatment effect (95%
CI; P value)2
－6.20 (－12.54, 0.14;
0.055)
－5.94 (－12.19, 0.31;
0.062)
－10.96 (－16.77,－
5.16; <0.001)
－10.56 (－16.53,－
4.60; 0.001)
－8.76 (－14.13,－
3.39; 0.002)
－8.52 (－13.80,－
3.23; 0.002)
－9.15 (－14.43,－
3.87; 0.001)
－9.45 (－14.60,－
4.30; < 0.001)
Notes: trial group was treated with conventional medication plus sugarcane bagasse pills orally (six pills twice daily for 30 days); control
group was treated with conventional medication plus placebo (six pills twice daily for 30 days). SGRQ: St. George's Respiratory Question-
naire; Mean D: mean difference; CI: confidence interval; ITT: intention-to-treat; PPS: per protocol set. Data are presented as mean (SD).
aP < 0.001, bP < 0.05, for the change between pre- and post-treatment (within-group difference analyzed by the paired t-test). 1The ITT
population was 91 in the trial group and 87 in the control group; the PPS population was 84 in the trial group and 82 in the control
group. 2Covariance analysis estimate with 95% CI for the difference.
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well-tolerated addition to pharmacotherapy for stable
COPD. This may be because sugarcane bagasse pills
are easier to take compared with drinking a decoction.
Furthermore, since sugarcane bagasse is a byproduct of
sugarcane processing, it is less expensive than other
TCM medicines. Therefore, sugarcane bagasse taken
orally as an adjuvant therapy has potential value in im-
proving HRQoL of patients with stable COPD.
Lung function testing was not used as an assessment in
our study. Although lung function test is an objective
indicator of airway limitation with FEV1 as a marker
for some pathophysiological changes in COPD, it still
correlates only poorly with the severity of dyspnea and
other symptoms.42 In addition, patients in this trial
were in the stable phase of COPD, so their lung func-
tion would not have obviously changed except under
acute exacerbation.
A limitation of our study is the relatively short treat-
ment period (30 days) and follow-up time (6 months),
which is not long enough to account for the frequency
and duration of acute exacerbations of COPD. Further
studies are required to confirm the long-term effects of
sugarcane bagasse on stable COPD.
In conclusion, sugarcane bagasse dietary fiber appears
to be a safe and effective adjuvant therapy that im-
proved quality of life in patients with stable COPD
during 6 months of follow-up. Although this study
demonstrates that sugarcane bagasse is an effective adju-
vant treatment for patients with stable COPD, further
studies are required to elucidate the mechanism of sug-
arcane bagasse for treating stable COPD.
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